Table 3.

Summary of SGLT2i RCTs including IgAN participants. eGFR as CKD-EPI

Trial	Key Inclusion criteria	Primary outcomes	Key exclusion criteria	Regimen	Outcome
DAPA-CKD	eGFR ≥25 and ≤75 ml/min per 1.73 m2, uPCR ≥200 and ≤5000 mg/g, stable + maximum tolerated single agent RAS blockade for 4 weeks	Sustained decline of eGFR by 50%, ESKD or death from cardio-renal causes	Immunosuppressive therapy, organ transplantation.	dapagliflozin 10 mg/day	Outcome occurred in 9.2% of treatment group vs. 14.5% in placebo group.
EMPA-KIDNEY	eGFR ≥20 and ≤45 ml/min per 1.73 m2 OR eGFR ≥45 and <90 ml/min per 1.73 m2 with uPCR ≥300 mg/g	Sustained decline of eGFR by 40% or to 10, ESKD, or death from cardio-renal causes	Immunosuppressive therapy, kidney transplant, dual RAS blockade.	empagliflozin 10 mg/day	Outcome occurred in 13.1% of treatment group vs. 16.9% in placebo group.

CKD-EPI, chronic kidney disease: epidemiology collaboration; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; IgAN, IgA nephropathy; RAS, renin-angiotensin system; RCT, randomized controlled trial; SGLT2i, sodium-glucose co-transporter-2 inhibitor; uPCR, urine protein-to-creatinine ratio.